HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Rimawi on Future Research Directions in Metastatic HER2+ Breast Cancer

November 11th 2021

Mothaffar Fahed Rimawi, MD, discusses future research directions in metastatic HER2-positive breast cancer.

Dr. Sammons on the Clinical Implications of DESTINY-Breast03 in HER2+ Breast Cancer

November 9th 2021

Sarah Sammons, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Esteva on the Impact of Subcutaneous Pertuzumab/Trastuzumab in HER2+ Breast Cancer

November 8th 2021

Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.

Dr. Esteva on Therapeutic Developments in HER2+ Breast Cancer

November 2nd 2021

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

Trial Launches to Evaluate Novel ADC in Previously Treated HER2+ Breast Cancer

October 19th 2021

The phase 2 ACE-Breast03 trial has been launched to evaluate the efficacy and safety of ARX788, an investigational antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer who have progressed on prior HER2-directed therapies.

New Subcutaneous, Oral, and Intravenous Therapies Transform Treatment in Early-Stage HER2+ Breast Cancer

October 18th 2021

Francisco Javier Esteva, MD, PhD, discussed the current approach to treating patients with early-stage HER2-positive breast cancer, unmet needs in the space, and future directions with neratinib and T-DM1.

Trastuzumab Duocarmazine Produces PFS Benefit in Pretreated HER2+ Breast Cancer

October 12th 2021

Vic-trastuzumab duocarmazine markedly improved progression-free survival vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received 2 prior treatment regimens or ado-trastuzumab emtansine in the metastatic setting, according to data from the phase 3 TULIP trial.

Harbeck Highlights Biomarkers for pCR, Survival After De-escalated Neoadjuvant T-DM1 in HER2+ Breast Cancer

October 7th 2021

Nadia Harbeck, MD, PhD, discusses the predictive impact of biomarkers on pathologic complete response and survival following de-escalated neoadjuvant T-DM1 with or without endocrine therapy in patients with hormone receptor–positive, HER2-positive breast cancer.

Dr. Harbeck on the Background of the WSG ADAPT-TP Trial in HR+, HER2+ Breast Cancer

October 6th 2021

Nadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.

Dr. Rimawi on Mitigating Interstitial Lung Disease in HER2+ Breast Cancer

October 4th 2021

Mothaffar Fahed Rimawi, MD, discusses mitigating interstitial lung disease/pneumonitis in HER2-positive breast cancer.

FDA Grants Breakthrough Therapy Designation to Trastuzumab Deruxtecan for Select HER2+ Metastatic Breast Cancer

October 4th 2021

The FDA has granted a breakthrough therapy designation to trastuzumab deruxtecan-nxki for use in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 1 or more anti–HER2-based regimens.

Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast Cancer

September 28th 2021

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Dr. Pegram on Unmet Clinical Needs in HER2+ Metastatic Breast Cancer

September 22nd 2021

Mark D. Pegram, MD, discusses unmet clinical needs in HER2-positive metastatic breast cancer.

Biomarkers May Predict Outcomes Following De-Escalated Neoadjuvant T-DM1 in HR+/HER2+ Early Breast Cancer

September 20th 2021

Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.

Trastuzumab Deruxtecan Bests T-DM1 in First Head-to-Head Study for HER2+ Breast Cancer

September 18th 2021

Fam-trastuzumab deruxtecan-nxki demonstrated a clinically meaningful and statistically significant improvement in progression-free survival vs standard of care trastuzumab emtansine for patients with previously treated HER2-positive metastatic breast cancer.

Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast Cancer

September 16th 2021

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

Dosing Strategies Help Personalize Care in HER2+ Breast Cancer

September 14th 2021

Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.

Single-Agent Trastuzumab Yields Superior Health-Related QoL in HER2+ Breast Cancer

September 3rd 2021

More detrimental effects on health-related quality of life were reported, and lasted for at least 12 months, with the combination of trastuzumab plus chemotherapy compared with trastuzumab alone in older patients with HER2-positive breast cancer, according to an analysis of the phase 3 RESPECT trial.

Zanidatamab Plus Tucatinib/Capecitabine Is Being Tested in Advanced HER2+ Breast Cancer

September 1st 2021

Zanidatamab is being combined with tucatinib and capecitabine in a new cohort of a phase 1 trial of patients with locally advanced and/or metastatic HER2-positive breast cancer.

Dr. Carey on the Updated Results of the PALOMA-3 Trial in HR+/HER2- Breast Cancer

August 16th 2021

Lisa A. Carey, MD, FASCO, discusses the updated results of the phase 3 PALOMA-3 trial in hormone receptor–positive, HER2-positive breast cancer.